NBTX
Nanobiotix S.A.NASDAQHealthcare$31.04-8.89%ClosedMarket Cap: $1.50B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-15.38
P/S
230.94
EV/EBITDA
-31.57
DCF Value
$9.72
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-765.4%
Net Margin
-899.7%
ROE
67.3%
ROA
-76.2%
ROIC
-301.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2025 | $26.6M | 100.0% | $808.0K | $-5.4M | $-0.11 | — |
| Q4 2024 | $-20.9M | 100.0% | $-44.7M | $-46.3M | $-0.98 | — |
| FY 2024 | $-11.6M | 100.0% | $-68.4M | $-68.1M | $-1.44 | — |
| Q2 2024 | $9.3M | 100.0% | $-23.7M | $-21.9M | $-0.46 | — |
| Q4 2023 | $32.9M | 100.0% | $-1.4M | $-11.6M | $-0.31 | — |
| FY 2023 | $36.2M | 100.0% | $-26.8M | $-39.7M | $-1.08 | — |
| Q2 2023 | $3.3M | 100.0% | $-25.4M | $-28.1M | $-0.80 | — |
| Q4 2022 | $1.7M | 56.3% | $-24.2M | $-30.7M | $-0.88 | — |
| FY 2022 | $4.8M | 79.4% | $-46.7M | $-57.0M | $-1.64 | — |
| Q2 2022 | $664.5K | -12.3% | $-26.2M | $-26.4M | $-0.76 | — |
| Q4 2021 | $664.0K | -14.3% | $-24.1M | $-16.6M | $-0.48 | — |
| FY 2021 | $2.6M | 100.0% | $-52.6M | $-47.0M | $-1.35 | — |